Excessive Daytime Sleepiness Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview
The Excessive Daytime Sleepiness (EDS) Market is projected to grow from USD 5,355 million in 2024 to an estimated USD 10,827.8 million by 2032, reflecting a compound annual growth rate (CAGR) of 9.2% during the forecast period.
The market is driven by the increasing prevalence of sleep disorders globally, often linked to lifestyle changes, stress, and chronic conditions. Rising awareness campaigns by healthcare organizations and governments about the importance of sleep health have encouraged early diagnosis and treatment. Furthermore, advancements in treatment options, including wakefulness-promoting agents, central nervous system stimulants, and cognitive-behavioral therapies, are enhancing patient outcomes. The integration of digital health solutions, such as wearable devices and mobile apps, for real-time sleep monitoring and management is also driving market growth. Additionally, the growing geriatric population, which is more susceptible to sleep disorders, further amplifies the demand for effective EDS management solutions.
Market Drivers
Advances in Diagnostic and Treatment Technologies:
Technological advancements in diagnostic tools and treatment modalities have significantly boosted the EDS market. Improved sleep monitoring devices, such as polysomnography and wearable sleep trackers, enable accurate and timely diagnosis, enhancing patient outcomes. For instance, Inspire Medical Systems introduced its Upper Airway Stimulation (UAS) therapy, a neurostimulation device approved by the FDA for treating moderate-to-severe obstructive sleep apnea. Additionally, the development of advanced pharmacological treatments, including wakefulness-promoting agents and central nervous system stimulants, has expanded therapeutic options for managing excessive daytime sleepiness. Non-pharmacological approaches, such as cognitive-behavioral therapy for sleep, are also gaining traction, providing comprehensive solutions for patients.
Market Challenges
High Cost of Diagnostic and Treatment Solutions:
The excessive daytime sleepiness market faces challenges associated with the high cost of diagnostic procedures and treatment options. Advanced diagnostic tools, such as polysomnography and wearable monitoring devices, are often expensive, limiting accessibility for patients in low- and middle-income regions. Similarly, newer pharmacological treatments with enhanced efficacy and safety profiles come with premium pricing, creating financial barriers for uninsured or underinsured patients. These cost-related challenges hinder widespread adoption and may delay timely diagnosis and treatment.
Segmentation
By Diseases:
Obstructive Sleep Apnea (OSA)
Narcolepsy
By Treatment:
Devices (Diagnostics, Therapy)
Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine Salts, Sodium Oxybate)
By Distribution Channels:
Hospitals & Sleep Laboratories
Home Care Settings
By End-User:
Hospitals
Sleep Clinics
Ambulatory Surgical Centers
Home Care Settings
By Region:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-East Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Avadel Pharmaceuticals
Becton, Dickinson and Company (BD)
BIOPROJET
BMC Medical Co. Ltd.
Braebon Medical Corporation
Cadwell Laboratories Inc. Ltd
Compumedics
Eisai Co., Ltd.
Fisher & Paykel Healthcare
GE Healthcare
GlaxoSmithKline plc
Hikma Pharmaceuticals
Jazz Pharmaceuticals
Koninklijke Philips N.V.
ResMed Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
The Excessive Daytime Sleepiness (EDS) Market is projected to grow from USD 5,355 million in 2024 to an estimated USD 10,827.8 million by 2032, reflecting a compound annual growth rate (CAGR) of 9.2% during the forecast period.
The market is driven by the increasing prevalence of sleep disorders globally, often linked to lifestyle changes, stress, and chronic conditions. Rising awareness campaigns by healthcare organizations and governments about the importance of sleep health have encouraged early diagnosis and treatment. Furthermore, advancements in treatment options, including wakefulness-promoting agents, central nervous system stimulants, and cognitive-behavioral therapies, are enhancing patient outcomes. The integration of digital health solutions, such as wearable devices and mobile apps, for real-time sleep monitoring and management is also driving market growth. Additionally, the growing geriatric population, which is more susceptible to sleep disorders, further amplifies the demand for effective EDS management solutions.
Market Drivers
Advances in Diagnostic and Treatment Technologies:
Technological advancements in diagnostic tools and treatment modalities have significantly boosted the EDS market. Improved sleep monitoring devices, such as polysomnography and wearable sleep trackers, enable accurate and timely diagnosis, enhancing patient outcomes. For instance, Inspire Medical Systems introduced its Upper Airway Stimulation (UAS) therapy, a neurostimulation device approved by the FDA for treating moderate-to-severe obstructive sleep apnea. Additionally, the development of advanced pharmacological treatments, including wakefulness-promoting agents and central nervous system stimulants, has expanded therapeutic options for managing excessive daytime sleepiness. Non-pharmacological approaches, such as cognitive-behavioral therapy for sleep, are also gaining traction, providing comprehensive solutions for patients.
Market Challenges
High Cost of Diagnostic and Treatment Solutions:
The excessive daytime sleepiness market faces challenges associated with the high cost of diagnostic procedures and treatment options. Advanced diagnostic tools, such as polysomnography and wearable monitoring devices, are often expensive, limiting accessibility for patients in low- and middle-income regions. Similarly, newer pharmacological treatments with enhanced efficacy and safety profiles come with premium pricing, creating financial barriers for uninsured or underinsured patients. These cost-related challenges hinder widespread adoption and may delay timely diagnosis and treatment.
Segmentation
By Diseases:
Obstructive Sleep Apnea (OSA)
Narcolepsy
By Treatment:
Devices (Diagnostics, Therapy)
Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine Salts, Sodium Oxybate)
By Distribution Channels:
Hospitals & Sleep Laboratories
Home Care Settings
By End-User:
Hospitals
Sleep Clinics
Ambulatory Surgical Centers
Home Care Settings
By Region:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-East Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Avadel Pharmaceuticals
Becton, Dickinson and Company (BD)
BIOPROJET
BMC Medical Co. Ltd.
Braebon Medical Corporation
Cadwell Laboratories Inc. Ltd
Compumedics
Eisai Co., Ltd.
Fisher & Paykel Healthcare
GE Healthcare
GlaxoSmithKline plc
Hikma Pharmaceuticals
Jazz Pharmaceuticals
Koninklijke Philips N.V.
ResMed Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Table of Contents
219 Pages
- CHAPTER NO. 1 : INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2 : EXECUTIVE SUMMARY
- 2.1. [Keyword] Snapshot
- 2.1.1. [Keyword], 2018 - 2032 (USD Million)
- CHAPTER NO. 3 : [Keyword] – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. [Keyword] Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups /SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6 : [Keyword] – BY [SEGMENT 1] ANALYSIS
- CHAPTER NO. 7 : [Keyword] – BY [SEGMENT 3] ANALYSIS
- CHAPTER NO. 8 : [Keyword] – BY [SEGMENT 4] ANALYSIS
- CHAPTER NO. 9 : [Keyword] – BY [SEGMENT 5] ANALYSIS
- CHAPTER NO. 10 : [Keyword] – BY [SEGMENT 8] ANALYSIS
- CHAPTER NO. 11 : COMPANY PROFILES
- 9.1. Avadel Pharmaceuticals
- 9.1.1. Company Overview
- 9.1.2. Product Portfolio
- 9.1.3. SWOT Analysis
- 9.1.4. Business Strategy
- 9.1.5. Financial Overview
- 9.2. Becton, Dickinson and Company (BD)
- 9.3. BIOPROJET
- 9.4. BMC Medical Co. Ltd.
- 9.5. Braebon Medical Corporation
- 9.6. Cadwell Laboratories Inc. Ltd
- 9.7. Compumedics
- 9.8. Eisai Co., Ltd.
- 9.9. Fisher & Paykel Healthcare
- 9.10. GE Healthcare
- 9.11. GlaxoSmithKline plc
- 9.12. Hikma Pharmaceuticals
- 9.13. Jazz Pharmaceuticals
- 9.14. Koninklijke Philips N.V.
- 9.15. ResMed Inc.
- 9.16. Takeda Pharmaceutical Company Limited
- 9.17. Teva Pharmaceutical Industries Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
